Act Now or Risk Everything: Viatris Investors Face Crucial Deadline Amid Fraud Allegations

The clock is ticking for investors in Viatris Inc. (NASDAQ: VTRS). With a June 3, 2025, deadline looming for lead plaintiff appointment in a major securities fraud lawsuit, shareholders must act swiftly to protect their rights—or risk forfeiting their chance to recover losses tied to the company’s alleged misstatements about critical FDA-related risks.

The Heart of the Matter: Downplaying FDA Warnings

The lawsuit, Quinn v. Viatris Inc., accuses the company and its executives of misleading investors about the severity of an FDA warning letter and import alert issued in late 2024. The FDA flagged serious compliance issues at Viatris’s Indore, India facility, which manufactures critical drugs like Lenalidomide. Despite these red flags, Viatris allegedly dismissed the risks as a “minor headwind,” downplaying their financial impact.

But the truth was stark: the FDA’s actions crippled the facility’s ability to produce and export medications, forcing Viatris to slash its 2025 revenue guidance by a staggering $1.4 billion. When the company finally revealed the full extent of the damage on February 27, 2025, its stock price plummeted by 15% in a single day, erasing $1.8 billion in market value.

Why the June 3 Deadline Matters

This is not a case for passive investors. The court has set June 3, 2025, as the deadline for filing motions to become lead plaintiff. The lead plaintiff will act as a representative for all shareholders who purchased Viatris shares between August 8, 2024, and February 26, 2025—the period during which the company allegedly made false statements.

Investors who miss this deadline forfeit their right to influence the lawsuit’s direction or seek compensation. Even if you’re not seeking lead plaintiff status, joining the class action is critical to preserving your recovery options.

The Legal Landscape: Experienced Firms, Proven Results

The case is being handled by high-profile law firms with a history of securing substantial recoveries for investors:
- Robbins Geller Rudman & Dowd LLP: A leader in securities litigation, having recovered over $2.5 billion in 2024 alone.
- Berger Montague PC: Known for its $1.6 billion MF Global settlement and a $2 billion+ recovery since 2020.
- Schall Law Firm and Bernstein Liebhard LLP: Both emphasize contingency fee models, ensuring plaintiffs incur no upfront costs.

These firms are leveraging the materiality of Viatris’s misstatements—evidenced by the stock’s dramatic drop—to build a strong case. If successful, this could set a precedent for holding pharmaceutical companies accountable for transparency failures.

Risk Mitigation Strategies for Investors

1. Act Before June 3: Contact an attorney immediately to evaluate eligibility and pursue lead plaintiff status. Even small investors can benefit from a settlement.
2. Document Your Losses: Keep records of Viatris purchases during the Class Period to substantiate claims.
3. Due Diligence Going Forward: This case underscores the need for investors to scrutinize corporate disclosures about regulatory risks, especially for companies reliant on global manufacturing.

The Bottom Line: Protect Your Rights or Perish

The FDA missteps at Viatris were not just operational failures—they were calculated misrepresentations that betrayed investor trust. For those who held shares during the Class Period, the path forward is clear: act before June 3 to recover losses and demand accountability.

In an era where corporate transparency is under constant scrutiny, this case serves as a cautionary tale. Investors must remain vigilant, demand truth, and take legal action when misled. The clock is ticking—don’t let inaction cost you.

For legal consultation, contact: Robbins Geller (800/449-4900), Berger Montague (Andrew Abramowitz at 215-875-3015), or Schall Law Firm directly.